单次大剂量前列腺SBRT中电磁追踪运动下的剂量重建
该研究基于I/II期ONE SHOT试验中15例接受单次19 Gy前列腺SBRT的患者,利用前列腺内电磁转发器(EMT)实时追踪分次内运动并重建实际递送剂量。结果显示分次内运动对靶区覆盖影响极小,PTV D98%中位相对剂量差异为-1.9%,临床靶区D98%中位差异仅-0.3%。
要点
- 单次前列腺SBRT中EMT运动追踪下靶区覆盖剂量差异很小
- PTV D98%中位相对剂量差异为-1.9%(范围-7.9%至-1.0%)
- 膀胱和直肠剂量参数有显著差异但多在可接受范围内
核心结论
- 在实时电磁追踪联合光束门控下,单次前列腺SBRT的分次内运动对靶区覆盖的剂量学影响极小。
研究设计与样本
- 分析I/II期ONE SHOT试验中15例接受单次19 Gy PTV和17 Gy尿道PRV照射的前列腺SBRT患者。
主要发现
- 递送期间EMT运动范围中位数(±SD)在前后、上下、左右轴分别为0.26±0.09、0.22±0.14、0.18±0.10 cm。
- 8例患者因靶区运动超出限值需要中断治疗,其中前后方向6例和/或上下方向4例。
- 运动编码重建计划与原始计划相比,PTV D98%中位相对剂量差异为-1.9%(范围-7.9%至-1.0%),D2%为+0.5%(范围-0.3%至1.7%)。
- 临床靶区D98%中位差异为-0.3%(范围-1.6%至0.5%),覆盖仍充分。
- 膀胱和直肠剂量参数在原始与重建计划间有显著差异,但多数仍在可接受限值内。
临床怎么用
- 对于单次前列腺SBRT,采用前列腺内电磁转发器实时追踪联合光束门控可有效控制分次内运动对靶区剂量的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To reconstruct the dose delivered during single-fraction urethra-sparing prostate stereotactic body radiotherapy (SBRT) accounting for intrafraction motion monitored by intraprostatic electromagnetic transponders (EMT). METHODS: We analyzed data of 15 patients included in the phase I/II "ONE SHOT" trial and treated with a single fraction of 19 Gy to the planning target volume (PTV) and 17 Gy to the urethra planning risk volume. During delivery, prostate motion was tracked with implanted EMT. SBRT was interrupted when a 3-mm threshold was trespassed and corrected unless the offset was transient. Motion-encoded reconstructed (MER) plans were obtained by splitting the original plans into multiple sub-beams with isocenter shifts based on recorded EMT positions, mimicking prostate motion during treatment. We analyzed intrafraction motion and compared MER to planned doses. RESULTS: The median EMT motion range (±SD) during delivery was 0.26 ± 0.09, 0.22 ± 0.14 and 0.18 ± 0.10 cm in the antero-posterior, supero-inferior, and left-right axes, respectively. Treatment interruptions were needed for 8 patients because of target motion beyond limits in the antero-posterior (n = 6) and/or supero-inferior directions (n = 4). Comparing MER vs. original plan there was a median relative dose difference of -1.9% (range, -7.9 to -1.0%) and of +0.5% (-0.3-1.7%) for PTV D98% and D2%, respectively. The clinical target volume remained sufficiently covered with a median D98% difference of -0.3% (-1.6-0.5%). Bladder and rectum dosimetric parameters showed significant differences between original and MER plans, but mostly remained within acceptable limits. CONCLUSIONS: The dosimetric impact of intrafraction prostate motion was minimal for target coverage for single-fraction prostate SBRT with real-time electromagnetic tracking combined with beam gating.
引用
- Jaccard M, Ehrbar S, Miralbell R, et al. Single-fraction prostate stereotactic body radiotherapy: Dose reconstruction with electromagnetic intrafraction motion tracking. Radiother Oncol. 2020. PMID: 33310011. doi:10.1016/j.radonc.2020.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。